Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women
Howard N Hodis, Wendy J Mack, Stanley P Azen, Roger A Lobo, Donna Shoupe, Peter R Mahrer, David P Faxon, Linda Cashin-Hemphill, Miguel E Sanmarco, William J French, Thomas L Shook, Thomas D Gaarder, Anilkumar O Mehra, Ramin Rabbani, Alex Sevanian, Asit B Shil, Mina Torres, K Heiner Vogelbach, Robert H Selzer, Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group, Howard N Hodis, Wendy J Mack, Stanley P Azen, Roger A Lobo, Donna Shoupe, Peter R Mahrer, David P Faxon, Linda Cashin-Hemphill, Miguel E Sanmarco, William J French, Thomas L Shook, Thomas D Gaarder, Anilkumar O Mehra, Ramin Rabbani, Alex Sevanian, Asit B Shil, Mina Torres, K Heiner Vogelbach, Robert H Selzer, Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group
Abstract
Background: In postmenopausal women with coronary artery disease, conjugated equine estrogen with or without continuous administration of medroxyprogesterone acetate has failed to slow the progression of atherosclerosis. Whether 17beta-estradiol (the endogenous estrogen molecule) alone or administered sequentially with medroxyprogesterone acetate can slow the progression of atherosclerosis is unknown.
Methods: We conducted a double-blind, placebo-controlled trial in 226 postmenopausal women (mean age, 63.5 years) who had at least one coronary-artery lesion. Participants were randomly assigned to usual care (control group), estrogen therapy with micronized 17beta-estradiol alone (estrogen group), or 17beta-estradiol plus sequentially administered medroxyprogesterone acetate (estrogen-progestin group). In all patients the low-density lipoprotein (LDL) cholesterol level was reduced to a target of less than 130 mg per deciliter. The primary outcome was the average per-participant change between base-line and follow-up coronary angiograms in the percent stenosis measured by quantitative coronary angiography.
Results: After a median of 3.3 years of follow-up, the mean (+/-SE) change in the percent stenosis in the 169 participants who had a pair of matched angiograms was 1.89+/-0.78 percentage points in the control group, 2.18+/-0.76 in the estrogen group, and 1.24+/-0.80 in the estrogen-progestin group (P=0.66 for the comparison among the three groups). The mean difference in the percent stenosis between the estrogen group and the control group was 0.29 percentage point (95 percent confidence interval, -1.88 to 2.46), and the mean difference between the estrogen-progestin group and the control group was -0.65 (95 percent confidence interval, -2.87 to 1.57).
Conclusions: In older postmenopausal women with established coronary-artery atherosclerosis, 17beta-estradiol either alone or with sequentially administered medroxyprogesterone acetate had no significant effect on the progression of atherosclerosis.
Copyright 2003 Massachusetts Medical Society
Source: PubMed